Antisoma took a look at Phase II results for its AS1402 program for breast cancer and decided to scrap the trial and the drug after deciding that it was unlikely that the study would deliver positive data. "While AS1402 was an early stage product and therefore not an important contributor to our overall value, we are of course disappointed that the drug was not able to provide benefit to breast cancer patients," said CEO Glyn Edwards. Release